Circulating tumor DNA analysis predicts recurrence and avoids unnecessary adjuvant chemotherapy in I-IV colorectal cancer.

ABSTRACT:

Background

Circulating tumor DNA (ctDNA) has emerged as a biomarker that can define the risk of recurrence after curative-intent surgery for patients with colorectal cancer (CRC). However, beyond the predictive power of postoperative ctDNA detection, the efficacy and potential limitations of ctDNA detection urgently need to be fully elucidated in a large cohort of CRC.

Objectives

To define potentially cured CRC patients through ctDNA monitoring following surgery.

Design

A prospective, multicenter, observational study.

Methods

We enrolled 309 patients with stages I-IV CRC who underwent definitive surgery. Tumor tissues were sequenced by a custom-designed next-generation sequencing panel to identify somatic mutations. Plasma was analyzed using a ctDNA-based molec

SUBMITTER: Fan W 

PROVIDER: S-EPMC10822076 | biostudies-literature | 2024

REPOSITORIES: biostudies-literature